EA200400881A1 - Азаарилпиперазины - Google Patents

Азаарилпиперазины

Info

Publication number
EA200400881A1
EA200400881A1 EA200400881A EA200400881A EA200400881A1 EA 200400881 A1 EA200400881 A1 EA 200400881A1 EA 200400881 A EA200400881 A EA 200400881A EA 200400881 A EA200400881 A EA 200400881A EA 200400881 A1 EA200400881 A1 EA 200400881A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nervous system
central nervous
compounds
disorders
solvates
Prior art date
Application number
EA200400881A
Other languages
English (en)
Inventor
Дейвид Реджиналд Адамс
Джонатан Марк Бентли
Тоби Джонатан Бленч
Пауль Хебайзен
Натаниел Джулиус Томас Монк
Ханс Рихтер
Штефан Рёвер
Джонатан Ричард Энтони Роффи
Свен Тейлор
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Верналис Рисерч Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг, Верналис Рисерч Лимитед filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA200400881A1 publication Critical patent/EA200400881A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

В заявке описаны соединения формулы (I), а также их фармацевтически приемлемые соли, сольваты и сложные эфиры, где R-Rимеют значения, указанные в п.1. Соединения могут использоваться в форме фармацевтических препаратов для лечения или профилактики нарушений центральной нервной системы, поражений центральной нервной системы, сердечно-сосудистых заболеваний, желудочно-кишечных нарушений, диабета, ожирения и приступов апноэ во сне.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400881A 2002-01-29 2003-01-17 Азаарилпиперазины EA200400881A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives
PCT/EP2003/000459 WO2003064423A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines

Publications (1)

Publication Number Publication Date
EA200400881A1 true EA200400881A1 (ru) 2005-02-24

Family

ID=9929954

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400881A EA200400881A1 (ru) 2002-01-29 2003-01-17 Азаарилпиперазины

Country Status (33)

Country Link
US (1) US7098337B2 (ru)
EP (1) EP1472255B1 (ru)
JP (1) JP4213042B2 (ru)
KR (1) KR100644004B1 (ru)
CN (1) CN1290847C (ru)
AR (1) AR038237A1 (ru)
AT (1) ATE318817T1 (ru)
AU (1) AU2003205622B2 (ru)
BR (1) BR0307291A (ru)
CA (1) CA2472954C (ru)
DE (1) DE60303791T2 (ru)
DK (1) DK1472255T3 (ru)
EA (1) EA200400881A1 (ru)
EC (1) ECSP045208A (ru)
ES (1) ES2259757T3 (ru)
GB (1) GB0202015D0 (ru)
GT (1) GT200300015A (ru)
HR (1) HRP20040653A2 (ru)
IL (1) IL162727A0 (ru)
MA (1) MA27097A1 (ru)
MX (1) MXPA04007147A (ru)
NO (1) NO20043547L (ru)
PA (1) PA8564001A1 (ru)
PE (1) PE20030847A1 (ru)
PL (1) PL371922A1 (ru)
PT (1) PT1472255E (ru)
RS (1) RS65704A (ru)
SI (1) SI1472255T1 (ru)
TN (1) TNSN04136A1 (ru)
TW (1) TW200307683A (ru)
UY (1) UY27627A1 (ru)
WO (1) WO2003064423A1 (ru)
ZA (1) ZA200405458B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012547A (es) * 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CA2543197A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
AR046132A1 (es) * 2003-10-24 2005-11-23 Solvay Pharm Gmbh Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
ATE514698T1 (de) * 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
WO2007057329A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
ATE448230T1 (de) 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2870019C (en) * 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
MX362184B (es) * 2012-08-06 2019-01-08 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
ATE263558T1 (de) 1998-08-14 2004-04-15 Hoffmann La Roche Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
JP3774118B2 (ja) 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ZA200405458B (en) 2006-02-22
BR0307291A (pt) 2004-12-07
IL162727A0 (en) 2005-11-20
GT200300015A (es) 2003-09-12
AR038237A1 (es) 2005-01-05
PT1472255E (pt) 2006-06-30
PL371922A1 (en) 2005-07-11
CA2472954C (en) 2009-04-28
GB0202015D0 (en) 2002-03-13
US20030207888A1 (en) 2003-11-06
HRP20040653A2 (hr) 2005-06-30
NO20043547L (no) 2004-08-25
US7098337B2 (en) 2006-08-29
MA27097A1 (fr) 2004-12-20
CN1625558A (zh) 2005-06-08
PA8564001A1 (es) 2003-09-05
PE20030847A1 (es) 2003-10-21
EP1472255B1 (en) 2006-03-01
MXPA04007147A (es) 2004-10-29
AU2003205622B2 (en) 2006-10-19
CA2472954A1 (en) 2003-08-07
ES2259757T3 (es) 2006-10-16
DE60303791D1 (en) 2006-04-27
KR100644004B1 (ko) 2006-11-10
EP1472255A1 (en) 2004-11-03
KR20040077885A (ko) 2004-09-07
TNSN04136A1 (en) 2007-03-12
DE60303791T2 (de) 2006-11-02
JP4213042B2 (ja) 2009-01-21
UY27627A1 (es) 2003-07-31
WO2003064423A1 (en) 2003-08-07
RS65704A (en) 2006-10-27
ATE318817T1 (de) 2006-03-15
ECSP045208A (es) 2004-09-28
JP2005521671A (ja) 2005-07-21
SI1472255T1 (sl) 2006-06-30
CN1290847C (zh) 2006-12-20
DK1472255T3 (da) 2006-07-10
TW200307683A (en) 2003-12-16

Similar Documents

Publication Publication Date Title
EA200400881A1 (ru) Азаарилпиперазины
GB9902047D0 (en) Chemical compounds XI
CA2417106A1 (en) Piperazine derivatives
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
JO2282B1 (en) Oxazole derivatives
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
WO2002072584A3 (en) Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
HK1075894A1 (en) Prucalopride-n-oxide
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
EA200602083A1 (ru) Новые пиперазиновые производные диалкилоксиндолов
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
DE60206391D1 (de) Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen